Ouk Michael, Edwards Jodi D, Colby-Milley Jessica, Kiss Alexander, Swardfager Walter, Law Marcus
Hurvitz Brain Sciences Program (Ouk, Colby-Milley, Swardfager), Sunnybrook Research Institute, University of Toronto; Departments of Pharmacology & Toxicology (Ouk, Swardfager) and Family & Community Medicine (Law), University of Toronto, Toronto, Ont.; University of Ottawa Heart Institute (Edwards); School of Epidemiology and Public Health (Edwards), University of Ottawa, Ottawa, Ont.; ICES (Kiss), Toronto, Ont.
CMAJ Open. 2020 Mar 10;8(1):E134-E141. doi: 10.9778/cmajo.20190184. Print 2020 Jan-Mar.
Cervical cancer screening reduces disease-specific mortality. This study aimed to estimate whether bipolar disorder or schizophrenia is associated with disparities in cervical cancer screening rates.
This was a retrospective population-based matched case-cohort study of community-dwelling women aged 19-69 in Ontario using linked health administrative databases. We used odds ratios (ORs), hazards ratios and rate ratios (RRs) adjusted for demographic characteristics and relevant comorbidities to compare cervical cancer screening outcomes between women with a diagnosis of bipolar disorder or schizophrenia to women without that history matched on key demographic characteristics, between 2003 and 2015.
In total, 1 245 457 women were identified for inclusion in the analyses, 119 948 with a diagnosis of bipolar disorder or schizophrenia, and 1 125 509 without. Over a median follow-up duration of 12.5 years, women with the exposure were 36% less likely to be screened (OR 0.64, 95% confidence interval [CI] 0.64-0.65) than those without, and they took longer to undergo screening (median 18.98 mo v. 16.63 mo; χ = 3718.2, < 0.001). They were also screened less frequently (median 6.16 yr v. 4.69 yr per screen; RR 0.85, 95% CI 0.84-0.85). These effects were consistent after we excluded the 86 475 women (6.9%) with suspected major depressive disorder, and they were larger for the 59 141 women (4.7%) not attached to a family physician.
Women with bipolar disorder or schizophrenia were less likely to undergo cervical cancer screening, their screening was delayed, and they were screened at a lower rate compared to women without this psychiatric history. This practice gap suggests a need to further address barriers to screening, including access to a family physician, among women with bipolar disorder or schizophrenia.
宫颈癌筛查可降低疾病特异性死亡率。本研究旨在评估双相情感障碍或精神分裂症是否与宫颈癌筛查率的差异有关。
这是一项基于人群的回顾性匹配病例队列研究,研究对象为安大略省19至69岁的社区居住女性,使用了关联的卫生行政数据库。我们使用了经人口统计学特征和相关合并症调整的优势比(OR)、风险比和率比(RR),来比较2003年至2015年间被诊断为双相情感障碍或精神分裂症的女性与无该病史且关键人口统计学特征匹配的女性之间的宫颈癌筛查结果。
总共确定了1245457名女性纳入分析,其中119948名被诊断为双相情感障碍或精神分裂症,1125509名无此诊断。在中位随访期12.5年中,有暴露因素的女性接受筛查的可能性比无暴露因素的女性低36%(OR 0.64,95%置信区间[CI] 0.64 - 0.65),且她们接受筛查的时间更长(中位时间18.98个月对16.63个月;χ = 3718.2,< 0.001)。她们接受筛查的频率也更低(每次筛查的中位时间6.16年对4.69年;RR 0.85,95% CI 0.84 - 0.85)。在排除86475名(6.9%)疑似患有重度抑郁症的女性后,这些影响仍然一致,对于59141名(4.7%)未与家庭医生签约的女性,影响更大。
与无此精神病史的女性相比,患有双相情感障碍或精神分裂症的女性接受宫颈癌筛查的可能性更小,筛查延迟,且筛查率更低。这种实践差距表明需要进一步解决筛查障碍,包括双相情感障碍或精神分裂症女性获得家庭医生服务的问题。